Therapeutic Antibody


CLM-101(YYB-101), as an anti-hepatocyte growth factor (HGF) antibody down-regulating HGF/c-Met pathway, shows excellent effects on various kinds of cancer models. It is a fully human IgG4 with the high binding affinity with pM level and shows good safety and PK profiles.

Phase1b/2a clinical trial in mCRC (Irinotecan combo) is now on-going in Korea

Mechanism of Action

HGF (Hepatocyte Growth Factor) and its receptor, c-Met, are reported to be excessively found in various human cancer tissues including brain, lungs, liver, prostate, colon, breasts and skin, and such excessive discovery highly correlates with prognosis of the patient and possible spread.

YYB101 not only strongly inhibits the binding between HGF and c-Met, but also effectively lowers blood HGF levels, thus inhibiting tumor growth and metastasis.

Technical Advantages

Existing Problems Our Technology Advantages
Antibody subtype IgG4 No ADCC, CDC
Epitope α-chain Unique epitope in α-chain of HGF which binds c-Met with high affinity
Affinity pM Higher affinity than competitor

Phase 1 Clinical Study Results

All cohorts up to 30 mg/kg remained without DLT.

YYB101 showed no significant adverse effect and only minor side effects, such as fatigue, rash, dizziness, etc.

Phase I PK/PD data showed almost completely neutralization of HGF in serum and ascites.

In 39 patients enrolled, partial response (PR) for >16.8 months was observed in 1 (2.5%) and stable disease (SD) was observed in 17 (43.5%).